August 2025
company established a partnership with Sheba Medical Center
MEDICAL BACKGROUND
27 MILLION CVC DRESSINGS ARE USED ANNUALLY GLOBALLY
Central venous catheters (CVCs):
Provide life-saving vascular access for patients requiring long-term intravenous therapy
Enable quick, reliable, and safe access to large veins, especially in critical conditions.
Commonly used for administration of fluids/nutrition/ blood, repeated blood sampling, hemodynamic monitoring, drug delivery or chemotherapy that cannot be given through a peripheral vein.
Providing large volumes of fluids at a high rate
Mostly used for patients with severe trauma injuries (e.g., car accidents), massive bleeding, major stroke or severe neurological injuries, severe pneumonia or pulmonary embolism, systemic response to infection (sepsis), heart failure or cardiogenic shock, and recovery from major surgeries such as heart or brain operations.
These infections are a significant concern in healthcare settings due to their potential severity.
CLABSI stands for Central Line-Associated Bloodstream Infection.
Challenge One: INFECTIONS
- CDC: 250,000 CLABSI in the US annually, and of these, 12-25% die.
- USA number of deaths from CLABSI can reach 62,500 annually.
Challenge Two: FIXATION SUTURES While sutures are a traditional method for securing CVCs to the body, alternative methods like tissue adhesives / anchor devices are increasingly used due to potential complications associated with sutures. Sutures increase the risk of infectious complications, pose a needlestick injury risk to the provider, prolong procedure time, and add suturing equipment costs. Source: CDC, Elsevier
INFECTION SITES
OUR STUDY RESULTS
We conducted a study on 60 patients with a CVC (primarily in the neck), just 4 days after catheter insertion, during which the catheters were covered with a 3M chlorhexidine dressing. We found significant bacterial colonization, most prominently beneath the catheter hub, suggesting a potential path of progression along the catheter and into the bloodstream, leading to CLABSI.
OUR NOVEL SOLUTION
A dual-layer CVC dressing that secures the catheter between two antiseptic gel layers, thereby reducing infections and providing stabilization that eliminates the need for sutures.
SOLUTION BENEFITS
✔ Dual antiseptic gel layers allows double antiseptic area
✔ Much larger gel area covers
insertion site and under the hub
✔ Dual-layer dressing creates significantly improved fixation
✔ Sutureless dressing allows cleaning under the hub and prevents blood & infections
✔ Transparent dressing area for quick clinical assessment
✔ Flexible to fit variable anatomy
ANTI CLABSI
All products are Easy to apply, secured for 7 days, CVC compatible, Sterile & hypoallergenic, however Anti CLABSI is the only CVC dressing that reduces infections and do no require fixation sutures, while uniquely offering antiseptic fixation in a dual-layer format.
VALUE PROPOSITION
Anti CLABSI is the only CVC dressing that dramatically reduces infections & eliminate fixation sutures.
USA MARKET
SIZE: CVCs
CVCs = Central Venous Catheters
In USA, 7 million CVCs are estimated to be inserted annually.
The US is the leading market for CVCs, with 7 M CVC dressing used annually, holding the largest market share. North America, as a region, is also a dominant force in the CVC market.
The hospital segment led the market with the largest revenue share of 35.56% in 2024, followed by the ambulatory surgical centers and specialty clinics.
Source:CitiusPharma
Midline Catheters Market
Share, by End-use, 2024 (%)
USA SALE
CHANNELS
The hospital or a specialty clinic network checks whether there is an existing agreement with the manufacturer of the product they wish to purchase. If not, the GPO negotiates with the manufacturer. Common US GPOs include.
The distributor holds inventory, places the actual order, and delivers it to the hospital or clinic.
Common US distributors:
Surgical centers or small specialty clinics usually purchase directly from the distributor (without a GPO).
USA | CLABSI COSTS
SAVING
The economic burden of CLABSI is estimated at $2.5B
annually in the US alone, that can be significantly reduced.
Catheter Related Bloodstream Infection Market
Size, by Indication, 2023–2033 (US$ Billion)
USA | IMPROVING HOSPITAL SCORES – A CRITICAL ADVANTAGE
HOSPITAL-ACQUIRED INFECTION RATES, INCLUDING CLABSI, ARE A KEY FACTOR IN NATIONAL HOSPITAL RANKINGS AND QUALITY METRICS IN THE US.
Better infection scores mean:
- Higher reimbursement from Medicare and other insurers
- Stronger public reputation
- Fewer penalties under value-based care programs
Even a modest improvement in CLABSI prevention can significantly impact a hospital’s financial and operational performance.
BUSINESS MODEL & MARKET POTENTIAL
Even a modest improvement in CLABSI prevention can significantly impact a hospital’s financial and operational performance.
Global Market Potential for CVC Dressing is $ 378 M Annually, of which $98 M only in USA.
TIMELINE
POWERING SUCCESS THROUGH FUNDING
TEAM
Eli Ben Haroosh
CEO, Chairman
A serial medical device entrepreneur, founder of Zero Candida Ltd., U.T.T. Ltd., Donnie-Life and more. Extensive experience in building & scaling successful ventures. Served as President of Vonetize, a provider of premium content & technology solutions. Today, he serves as board member and president in several companies focused on medical R&D.
Yosh Dolberg
VP Engineering
A senior VP and medical device engineer, founder and former Head of R&D at biotech company UroGen Pharma, which develops innovative treatments for rare cancers and urological diseases. An expert in photoacoustic imaging, he is a co-author of a publication on photoacoustic imaging of the eye.
Tamar Ish Cassit
VP R&D
An entrepreneur, industrial design lead, military medic and a business consultant. Over 15 years of experience in design & production lines establishment for medical devices. Former Founder & CEO of medical device company, military medic, and lectured at HIT for product design and business development
Asher Holzer, Phd
Chief Scientist
A serial entrepreneur and senior executive in the medical device industry, with over 30 years of experience founding and leading public companies that developed and marketed breakthrough medical technologies, including UroGen, InspireMD, BioSig, and TheraCoat. Asher holds a PhD in Nuclear Physics from the Hebrew University and has a longstanding passion for innovation and excellence in medicine.
Isaac Tal, PhD
VP Operations
MBA in Healthcare Innovation, BA in Psychology & Human Services. Over two decades of experience in clinical operations, business development, and strategic planning in the medical and pharmaceutical industries. His career spans roles in hospitals, pharma companies, and health-tech ventures, including leadership positions in commercialization and growth strategy across
global markets.
Yakir Buaron
Design Manager
An industrial designer and product developer with a focus on medical devices & healthcare technology. He designs and prototypes medical products, and provides end‑to‑end support from concept through functional models. He collaborates with leading healthcare organizations like Sheba Medical Center and lectures at Shenkar College on design and innovation
ADVISORY BOARD
Dr. Eran Segal
Chief Medical Board
Director of the Division of Critical Care Medicine at Sheba Medical Center. Served as an IDF physician, and trained in anesthesiology at Hadassah & Sheba.
Completed Critical Care fellowship (ACGME-accredited) at the Florida Uni., specializing in respiratory failure & hemodynamic monitoring.Led Sheba’s General ICU for 14 years, and was the Director of Anesthesia and Critical Care at Assuta for 13 years. Now leading
AI-integrated critical care, extracorporeal life support, and data-driven quality initiatives. A global lecturer on digital ICUs & hemodynamic monitoring.
Dr. Yonatan Gargi
Medical Board
Senior anesthesiologist and intensive care physician at Sheba Medical Center, Israel’s leading hospital, with over 20 years of clinical experience. He is a principal investigator in multiple cutting-edge projects, including non-invasive bioimpedance-based fluid monitoring and AI-driven models to enhance clinical decision-making and optimize nutritional strategies in critically ill patients. Dr. Gargi holds several patents through Sheba ARC, including technologies for the prevention of CLABSI and VAP, as well as innovations in airway management and endoscopic interventions.
Dr. Amir Cohen
Medical Board
General Surgeon since 2006. General ICU Expert since 2013. The Head of the trauma and surgical Service in The Sheba Medical center, since 2022. The head of the General ICU in The Sheba Medical center, 2025.
Valeria Nudelman
Medical Board
Nurse, Clinical Supervisor, Intensive Care.
